RP1

Drug identity checked against registry records

Also recorded as Genetically modified herpes simplex type 1 virus

A drug appearing in a clinical trial does not mean it is FDA-approved. Check the original regulatory source for any approval claim.

Included trials

TrialSponsorPhaseStatusPrimary completion
Study of RP1 Monotherapy and RP1 in Combination With Nivolumab (IGNYTE)NCT03767348Replimune, Inc.Phase 2Active not recruiting2028-06Estimated
Study Evaluating Cemiplimab Alone and Combined With RP1 in Treating Advanced Squamous Skin CancerNCT04050436Replimune, Inc.Phase 2Active not recruiting2025-09Estimated

Regulatory dates and decisions

No regulatory events match this view.This does not mean no FDA events have occurred.